The German company’s lead product candidate is adrecizumab, a clinical-stage, first-in-class monoclonal antibody that targets the vasoprotective peptide adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascular leakage, congestion and shock.

In January 2021, the company named former Boehringer Ingelheim executive Wolfgang Baiker its chief executive.